StreetAlpha.app
Home › Stocks › BCRX

Biocryst Pharmaceuticals Inc (BCRX)

Healthcare
$7.50
▲ +0.67%
LAST CLOSE · NOV 17

BioCryst Pharmaceuticals develops and sells medicines for hereditary angioedema and other rare diseases. It last closed at $7.50 on Nov 17, up 0.67% on the day. The average 12-month price target from 4 analysts is $14.25 (+90.0% from the last close), with a high of $17.00 and a low of $11.00. Analyst consensus is Buy, based on the latest ratings from 4 firms (2 buy, 2 hold, 0 sell).

AI Auto Pilots
Is BCRX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$961.5M
+60.3% vs a year ago
Net income
−$359.7M
−37.4% margin
EPS (diluted)
−$1.28
Free cash flow
$365.8M
38.0% margin
Valuation
Market cap
$1.9B
257.3M shares
P/E
–
No P/E while losing money
Price to sales
2.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$97.0M
At Sep 30
Debt
$395.6M
At Sep 30
Shareholder equity
−$397.4M
Shares outstanding
257.3M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $157.2M$157.2MFY2021FY2022: $270.8M$270.8MFY2022FY2023: $331.4M$331.4MFY2023FY2024: $450.7M$450.7MFY2024FY2025: $874.8M$874.8MFY2025

From BCRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
4firms
2 Buy2 Hold0 Sell
Each firm's latest rating on BCRX in the past 90 days
Average 12-month target
$14.25
▲ 90.0% upside

Based on 4 analysts who set a price target on BCRX in the past 90 days. The average target is $14.25, with a high of $17.00 and a low of $11.00, compared with the last close of $7.50.

$7$10$14$18PAST 10 TRADING DAYS12-MONTH TARGETSHIGH $17AVG $14.25LOW $11May 27LAST CLOSE+12 MO$7$10$14$18PAST 10 DAYSTARGETSHIGH $17AVG $14.25LOW $11May 27LAST CLOSE+12 MO
Highest target$17.00
Average target$14.25
Lowest target$11.00
Latest rating changes
WedbushTarget lowered
Nov 5Buy$20 → $17
JP MorganTarget raised
Sep 30Hold$12 → $13
RBC CapitalDowngrade
Sep 10Hold$14 → $11
NeedhamReiterated
Sep 8Buy$16
WedbushMaintained
Aug 6Buy$20
DateFirmActionRatingPrice target
Nov 5WedbushTarget loweredBuy$20 → $17
Sep 30JP MorganTarget raisedHold$12 → $13
Sep 10RBC CapitalDowngradeHold$14 → $11
Sep 8NeedhamReiteratedBuy$16
Aug 6WedbushMaintainedBuy$20
Loading…

Technical Analysis

BCRX · as of the Nov 17 close · updated after every close
Downtrend

The stock is 5% below its 20 day and 9% below its 50 day average. It is 17% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 39). The nearest support is the Pivot at $7.45, and the nearest resistance the Pivot R1 at $7.57.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 4.4%/day
Key levels
$11.2252 week high+49.6%
$8.94100 day average+19.2%
$8.81200 day average+17.5%
$8.1550 day average+8.7%
$7.9020 day average+5.3%
$7.78Swing high (Nov 12)+3.7%
$7.57Pivot R1+0.9%
$7.50Last close
$7.45Pivot−0.7%
$7.38Pivot S1−1.6%
$7.38Swing low (Nov 6)−1.6%
$6.2352 week low−16.9%
Indicators
RSI (14)39.36Weak, oversold below 30Neutral
MACD-0.21Below its signal lineBearish
Stochastic10.5Near the bottom of its rangeOversold
ADX (14)15.2No clear trend
Williams %R-88.8Oversold below −80, overbought above −20Oversold
CCI (20)-95.6Oversold below −100, overbought above 100Neutral
Rate of change−12.5%Change over 10 sessionsBearish
ATR (14)$0.33Typical daily range, 4.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BCRX

What happened before

See how BCRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow BCRX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How BCRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in BCRX in the last 90 days.

Loading…

See today’s whale options flow across the market →

BCRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●149 buying vs 165 selling
  • ▼Held by funds -7.8 pts
  • ▲Funds holding +15
  • ▼Superinvestors: 2 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding334319+4.7%
In funds' top 1010–
Held by funds94.8%102.5%−7.8 pts
New / increased52 / 9753 / 133−19.9%
Reduced / sold out127 / 3885 / 38+34.1%
Put/call ratio0.000.01−90.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BCRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BCRX is in one of them and how their past BCRX trades turned out.

BCRX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BCRX in an article yet. Here's the latest on the wider market.

BCRX Congress Trades

All congress trades →
Trades, 12 months
2
Buys
2
100%
Sells
0
0%
People
1
Last filed Sep 4
Who traded BCRX · since 2023
Latest 4 filings
$1K – $15KTraded Jul 10, 2026Filed Sep 4, 2026
$1K – $15KTraded Nov 13, 2025Filed Dec 15, 2025
$1K – $15KTraded Oct 16, 2023Filed Nov 11, 2023
$1K – $15KTraded Sep 15, 2023Filed Oct 15, 2023
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CABuy$1K – $15KJul 10, 2026Sep 4, 202656 d
Gilbert CisnerosD · CABuy$1K – $15KNov 13, 2025Dec 15, 202532 d
Josh GottheimerD · NJBuy$1K – $15KOct 16, 2023Nov 11, 202326 d
Josh GottheimerD · NJSell$1K – $15KSep 15, 2023Oct 15, 202330 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Biocryst Pharmaceuticals

BioCryst Pharmaceuticals is a biotechnology company based in Durham, North Carolina. It develops and sells medicines for hereditary angioedema and other rare diseases. Its main product, ORLADEYO, is an oral medicine taken once daily to prevent attacks of hereditary angioedema, and it is approved in the United States and several other markets. The company also has RAPIVAB, an intravenous treatment for influenza, approved in several countries. Its customers include patients with these conditions, along with the healthcare providers and insurers who support their care.

Headquarters
Durham, NC
Founded
1986